ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

July 1, 2026

Dana-Farber

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#2

Harvard

Cambridge, MA
Key Differentiators
- Oncology
#3

University of Chicago

Chicago, IL
Key Differentiators
- Oncology
#4

Dana-Farber/Brigham and Women’s Cancer Center

Boston, MA
Key Differentiators
- Oncology
#5

University of Virginia

Charlottesville, VA
Key Differentiators
- Oncology